# Elritercept PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/elritercept

> The next catalyst for elritercept, sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), is its topline data readout, Feb to May 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | elritercept |
| Codes | KER-050, TAK-226 |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | very low-, low-, or intermediate-risk mds, wide range of patients with disorders, lower-risk mds in december 2024, [Myelofibrosis](https://sec-api.dev/indications/myelofibrosis), [Myelodysplastic Syndromes](https://sec-api.dev/indications/myelodysplastic-syndromes), Myelodysplastic Syndrome |
| Modality | fusion_protein |
| FDA designations | fast track |

## Timeline

### Dec 2024: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: lower-risk MDS in December 2024.
- First seen 2025-02-26, last confirmed 2025-02-26.
- SEC Form 10-K (accession 0001664710-25-000018): "We initiated our Phase 3 clinical trial of elritercept in patients with lower-risk MDS in December 2024." https://www.sec.gov/Archives/edgar/data/1664710/000166471025000018/kros-20241231.htm

### July 17, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 3. Indication: very low-, low-, or intermediate-risk MDS.
- First seen 2025-07-17, last confirmed 2026-11-05.
- SEC Form 8-K (accession 0001664710-25-000062): "On July 17, 2025, Keros Therapeutics, Inc. (the "Company") issued a press release announcing that the first patient was dosed in the Phase 3 RENEW clinical trial of elritercept in adults with transfusion-dependent anemia with very low, low, or intermediate risk myelodysplastic syndromes." https://www.sec.gov/Archives/edgar/data/1664710/000166471025000062/kros-20250717.htm
- Press release filed with the SEC (EX-99) (accession 0001664710-25-000062): "LEXINGTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that the first patient was dosed in the Phase 3 RENEW clinical trial of elritercept in adults with transfusion-dependent anemia with very low, low, or intermediate risk myelodysplastic syndromes ("MDS")." https://www.sec.gov/Archives/edgar/data/1664710/000166471025000062/exhibit99171725pr.htm
- SEC Form 10-Q (accession 0001664710-26-000066): "In July 2025, we announced that the first patient was dosed in the placebo-controlled Phase 3 RENEW clinical trial in patients with very low-, low-, or intermediate-risk MDS, which we refer to as lower-risk MDS." https://www.sec.gov/Archives/edgar/data/1664710/000166471026000066/kros-20260930.htm
- SEC Form 10-Q (accession 0001664710-26-000049): "In July 2025, we announced that the first patient was dosed in the placebo-controlled Phase 3 RENEW clinical trial in patients with very low-, low-, or intermediate-risk MDS, which we refer to as lower-risk MDS." https://www.sec.gov/Archives/edgar/data/1664710/000166471026000049/kros-20260630.htm
- SEC Form 10-Q (accession 0001664710-26-000030): "In July 2025, we announced that the first patient was dosed in the placebo-controlled Phase 3 RENEW clinical trial in patients with very low-, low-, or intermediate-risk MDS, which we refer to as lower-risk MDS." https://www.sec.gov/Archives/edgar/data/1664710/000166471026000030/kros-20260331.htm
- SEC Form 10-K (accession 0001664710-26-000018): "In July 2025, we announced that the first patient was dosed in the placebo-controlled Phase 3 RENEW clinical trial in patients with very low-, low-, or intermediate-risk MDS, which we refer to as lower-risk MDS." https://www.sec.gov/Archives/edgar/data/1664710/000166471026000018/kros-20251231.htm
- SEC Form 10-Q (accession 0001664710-25-000089): "In July 2025, we announced that the first patient was dosed in the Phase 3 RENEW clinical trial." https://www.sec.gov/Archives/edgar/data/1664710/000166471025000089/kros-20250930.htm
- SEC Form 10-Q (accession 0001664710-25-000070): "In July 2025, we announced that the first patient was dosed in the Phase 3 RENEW clinical trial." https://www.sec.gov/Archives/edgar/data/1664710/000166471025000070/kros-20250630.htm

### Feb to May 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Myelofibrosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05037760 (A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT05037760

### February 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Myelofibrosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05037760 (A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT05037760

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Myelodysplastic Syndromes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07319845 (A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-26 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07319845

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Myelodysplastic Syndromes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07319845 (A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-26 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07319845

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Myelodysplastic Syndromes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06499285 (A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06499285

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Myelodysplastic Syndromes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06499285 (A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06499285

### Apr to Jul 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Myelodysplastic Syndrome; Anemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07422480 (A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-30 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07422480

### April 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Myelodysplastic Syndrome; Anemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07422480 (A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-30 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07422480

### Oct 2029 to Jan 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Myelodysplastic Syndromes; Cytopenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04419649 (A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-10-30 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT04419649

### October 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Myelodysplastic Syndromes; Cytopenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04419649 (A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-10-30 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT04419649

### Dec 2029 to Mar 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Myelofibrosis; Anemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07623161 (A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-07 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07623161

### December 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Myelofibrosis; Anemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07623161 (A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-07 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07623161

## Same indication

- [Decitabine](https://sec-api.dev/pdufa/decitabine) (NVS)
- [RYTELO (imetelstat)](https://sec-api.dev/pdufa/imetelstat) (GERN)
- [Itacitinib](https://sec-api.dev/pdufa/itacitinib) (INCY)
- [Luspatercept](https://sec-api.dev/pdufa/luspatercept) (BMY)
- [OJJAARA (momelotinib)](https://sec-api.dev/pdufa/momelotinib) (GSK)
- [Oral azacitidine](https://sec-api.dev/pdufa/oral-azacitidine) (BMY)
- [Rinvatercept](https://sec-api.dev/pdufa/rinvatercept) (KROS)
- [Evrenzo® (roxadustat)](https://sec-api.dev/pdufa/roxadustat) (KYNB)
- [Tebapivat](https://sec-api.dev/pdufa/tebapivat) (AGIO)

Calendar months: [February 2028](https://sec-api.dev/fda-calendar/2028-02), [June 2028](https://sec-api.dev/fda-calendar/2028-06), [September 2028](https://sec-api.dev/fda-calendar/2028-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/elritercept.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Elritercept PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/elritercept

```bibtex
@misc{secapidev_pdufa_elritercept_20261116,
  title        = {Elritercept PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/elritercept}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_elritercept_20261116","title":"Elritercept PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/elritercept","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
